Search

Displaying results 4901 - 4910 of 8974 in total
  1. Drug

    Biguanide

    go.drugbank.com/drugs/DB13100
    ApprovedInvestigationalWithdrawn

    Biguanide has been investigated for the treatment of Diabetes Mellitus.

  2. Drug

    Meclocycline

    go.drugbank.com/drugs/DB13092
    Investigational

    Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .

    Categories: Anti-Acne Preparations for Topical Use, Antiinfectives for Treatment of Acne
  3. Drug

    Lisuride

    go.drugbank.com/drugs/DB00589
    Approved

    An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More Rings
  4. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

  5. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  6. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  7. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

  8. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  9. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents. … INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.

  10. Drug

    Pentolinium

    go.drugbank.com/drugs/DB01090
    Approved

    Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.